Carbetapentane

Catalog No.S0869 Synonyms: Pentoxyverine, CB

For research use only.

Carbetapentane (Pentoxyverine, CB) is an antitussive anticonvulsant nonselective sigma-1 (σ1) agonist.

Carbetapentane Chemical Structure

CAS No. 77-23-6

Purity & Quality Control

Choose Selective Sigma Receptor Inhibitors

Biological Activity

Description Carbetapentane (Pentoxyverine, CB) is an antitussive anticonvulsant nonselective sigma-1 (σ1) agonist.
Targets
σ1 [1]

Protocol (from reference)

Chemical Information

Molecular Weight 333.46
Formula

C20H31NO3

Density 1.048 g/mL
CAS No. 77-23-6
Storage 2 years -20°C liquid
Smiles CCN(CC)CCOCCOC(=O)C1(CCCC1)C2=CC=CC=C2

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

mg/kg g μL

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO % % Tween 80 % ddH2O
%DMSO %

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Interventions Conditions Sponsor/Collaborators Start Date Phases
NCT05464836 Not yet recruiting Drug: CB-103|Drug: Venetoclax Leukemia Lymphoblastic|Leukemia M.D. Anderson Cancer Center December 30 2022 Phase 2
NCT05301361 Not yet recruiting Drug: Methylphenidate Oral Solution Intellectual Disability|Fragile X Syndrome|Down Syndrome|Attention Deficit Hyperactivity Disorder University of California Davis November 1 2022 Phase 1
NCT05472558 Not yet recruiting Biological: anti-CD19 CAR-NK B-cell Non Hodgkin Lymphoma Second Affiliated Hospital School of Medicine Zhejiang University August 1 2022 Phase 1
NCT05312372 Not yet recruiting Drug: Combination (S095033 + paclitaxel) Esophageal Squamous Cell Carcinoma Institut de Recherches Internationales Servier|ADIR a Servier Group company|Servier August 2022 Phase 1|Phase 2
NCT03863145 Active not recruiting Drug: CB-03-10 Advanced Refractory Solid Tumors|Subjects Considered Likely to Respond to CB-03-10 Cosmo Technologies Ltd|Cosmo Pharmaceuticals NV June 14 2022 Early Phase 1

(data from https://clinicaltrials.gov, updated on 2022-08-01)

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.

* Indicates a Required Field

Please enter your name.
Please enter your email. Please enter a valid email address.
Please write something to us.
Tags: buy Carbetapentane | Carbetapentane supplier | purchase Carbetapentane | Carbetapentane cost | Carbetapentane manufacturer | order Carbetapentane | Carbetapentane distributor